Literature DB >> 20878879

The use of saliva as a biological fluid in relative bioavailability studies: comparison and correlation with plasma results.

M Esperanza Ruiz1, Paula Conforti, Pietro Fagiolino, M Guillermina Volonté.   

Abstract

The aim of the present study was to present new evidence supporting the use of saliva as a biological fluid in relative bioavailability studies. Carbamazepine was chosen as a model drug because of its suitability for salivary therapeutic drug monitoring and its well-documented plasma bioavailability. A relative bioavailability study of four different immediate release carbamazepine products was performed. Stimulated saliva samples were collected by chewing on parafilm wax and by the spitting method. In vitro dissolution testing of formulations, using 900 ml of 1% sodium lauryl sulphate in water, was also carried out. The in vitro-in vivo correlations obtained in this salivary study were consistent with previous correlations assessed using plasma. These results support the suitability of saliva as the biological fluid in relative bioavailability studies.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20878879     DOI: 10.1002/bdd.728

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  11 in total

1.  Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer?

Authors:  Janet Hardy; Ross Norris; Helen Anderson; Angela O'Shea; Bruce Charles
Journal:  Support Care Cancer       Date:  2011-04-15       Impact factor: 3.603

2.  Is saliva suitable as a biological fluid in relative bioavailability studies? Analysis of its performance in a 4 x 2 replicate crossover design.

Authors:  M Esperanza Ruiz; Pietro Fagiolino; Perla M de Buschiazzo; M Guillermina Volonté
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-06-30       Impact factor: 2.441

3.  Predicting smoking abstinence with biological and self-report measures of adherence to varenicline: Impact on pharmacogenetic trial outcomes.

Authors:  Annie R Peng; Robert Schnoll; Larry W Hawk; Paul Cinciripini; Tony P George; Caryn Lerman; Rachel F Tyndale
Journal:  Drug Alcohol Depend       Date:  2018-06-26       Impact factor: 4.492

4.  Stability of Varenicline Concentration in Saliva Over 21 Days at Three Storage Temperatures.

Authors:  Maria Novalen; Meghan J Chenoweth; Bin Zhao; Larry W Hawk; Rachel F Tyndale
Journal:  Nicotine Tob Res       Date:  2022-02-01       Impact factor: 5.825

5.  A high performance liquid chromatographic assay of mefloquine in saliva after a single oral dose in healthy adult Africans.

Authors:  Grace O Gbotosho; Christian T Happi; Omowunmi Lawal; Abayomi Sijuade; Akin Sowunmi; Ayoade Oduola
Journal:  Malar J       Date:  2012-02-27       Impact factor: 2.979

6.  Saliva versus plasma bioequivalence of rusovastatin in humans: validation of class III drugs of the salivary excretion classification system.

Authors:  Nasir Idkaidek; Tawfiq Arafat
Journal:  Drugs R D       Date:  2015-03

7.  Solid Phase Extraction Purification of Saliva Samples for Antipsychotic Drug Quantitation.

Authors:  Ewelina Dziurkowska; Marek Wesolowski
Journal:  Molecules       Date:  2018-11-12       Impact factor: 4.411

8.  Simultaneous Quantification of Antipsychotic and Antiepileptic Drugs and Their Metabolites in Human Saliva Using UHPLC-DAD.

Authors:  Ewelina Dziurkowska; Marek Wesolowski
Journal:  Molecules       Date:  2019-08-14       Impact factor: 4.411

9.  Comparative assessment of saliva and plasma for drug bioavailability and bioequivalence studies in humans.

Authors:  Nasir M Idkaidek
Journal:  Saudi Pharm J       Date:  2016-10-17       Impact factor: 4.330

10.  Deproteinization as a Rapid Method of Saliva Purification for the Determination of Carbamazepine and Carbamazepine-10,11 Epoxide.

Authors:  Ewelina Dziurkowska; Marek Wesolowski
Journal:  J Clin Med       Date:  2020-03-27       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.